Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Pharma Holdings, Inc. (CPHI)
Haikou, CN
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -16.13% | +86.38% | +55.55% | +65.08% | -30.67% | -14.05% | -51.85% | -93.62% | -99.66% | -99.08% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-8.5% Q1'26: +86,556,905.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-174.1% Q1'26: +75.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+316.7% Q1'26: -5.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-74.5% Q1'26: 0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-75.4% ★ Q1'26: +501.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-121,602.55× Q1'26: -0.04× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2012 actual |
|---|---|
| Revenue |
54.51M
est: 99.22M (-45.1%)
|
| EBITDA |
7.37M
est: -9.96M (+174.0%)
|
| EBIT |
5.91M
est: -46.86M (+112.6%)
|
| Net Income |
4.62M
|
| SGA |
6.41M
est: 37.60M (-83.0%)
|
| EPS |
1.06
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ke Deng | 15.52M | 19.40% | 10.00 | — | 15.52M | — | IN | China | 2023-03-09 | ↗ |
| 2 | Tao Liu | 15.00M | 27.30% | 15.00M | — | 15.00M | — | IN | China | 2024-01-26 | ↗ |
| 3 | John M. Fife | 4.99M | 9.99% | 4.99M | — | 4.99M | — | IN | — | 2022-09-27 | ↗ |
| 4 | Streeterville Capital LLC85-2954598 | 4.99M | 9.99% | 4.99M | — | 4.99M | — | OO | — | 2022-09-27 | ↗ |
| 5 | Streeterville Management LLC85-3223919 | 4.99M | 9.99% | 4.99M | — | 4.99M | — | OO | — | 2022-09-27 | ↗ |
| 6 | (: | 2.78M | 9.26% | 2.78M | — | 2.78M | — | IN | United States | 2005-10-27 | ↗ |
| 7 | Peter Siris | 2.76M | 6.50% | 12.0K | 2.75M | 12.0K | 2.75M | IN | OR PLACE OF ORGANIZATION | 2010-02-16 | ↗ |
| 8 | Guerrilla Capital Management, LLC | 2.75M | 6.40% | — | 2.75M | — | 2.75M | OO | OR PLACE OF ORGANIZATION | 2010-02-16 | ↗ |
| 9 | Leigh S. Curry | 2.48M | 5.70% | — | 2.48M | — | 2.48M | IN | United States | 2012-02-14 | ↗ |
| 10 | HEARTLAND ADVISORS, INC. | 2.44M | 5.60% | — | 2.30M | — | — | IA | WISCONSIN USA | 2012-02-10 | ↗ |
| 11 | WILLIAM J. NASGOVITZ | 2.44M | 5.60% | — | 2.30M | — | — | IN | WISCONSIN USA | 2012-02-10 | ↗ |
| 12 | 62-1871308 | 2.22M | 11.00% | — | — | — | — | IA | Citizenship or Place of Organization Tennessee | 2013-02-14 | ↗ |
| 13 | 26-0281944 | 52.8K | 11.00% | — | — | — | — | OO | Citizenship or Place of Organization Delaware | 2013-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-28 | Liu Tao (Chengdu) | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 15,000,000 | — | ↗ |
| 2023-09-29 | Li Zhilin | Director / Officer / 10% Owner | A-Award | A | Common Stock | 13,757,063 | 0.14 | 1.93M | 15,138,063 | — | ↗ |
| 2022-12-30 | Deng Ke | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,552,230 | — | ↗ |
| 2021-09-09 | Li Zhilin | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,760,000 | 0.67 | 1.18M | 13,810,000 | — | ↗ |
| 2020-12-23 | Li Zhilin | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,000,000 | 0.00 | — | 12,050,000 | — | ↗ |
| 2012-04-28 | WAUNG FRANK | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 138,415 | — | ↗ |
| 2011-05-25 | WAUNG FRANK | Officer | A-Award | A | Non-Qualified Stock Option | 25,000 | 2.54 | 63.5K | 25,000 | — | ↗ |
| 2011-05-25 | Li Zhilin | Director / Officer / 10% Owner | A-Award | A | Common Stock | 50,000 | 0.00 | — | 10,050,000 | — | ↗ |
| 2010-12-13 | WAUNG FRANK | Officer | A-Award | A | Common Stock | 6,863 | 0.00 | — | 13,415 | — | ↗ |
| 2010-11-15 | WAUNG FRANK | Officer | M-Exempt | D | Stock Option | 40,000 | 2.75 | 110.0K | 260,000 | — | ↗ |
| 2010-04-28 | WAUNG FRANK | Officer | D-Return | D | Stock Option(Right to Buy) | 150,000 | 3.47 | 520.5K | 0 | — | ↗ |
| 2010-02-09 | Tsui Heung Mei | Director / 10% Owner | A-Award | D | Common Stock, par value $0.001 per share | 1,500,000 | 3.00 | 4.50M | 9,312,651 | — | ↗ |
| 2009-10-13 | WAUNG FRANK | Officer | D-Return | D | Stock Option(Right to Buy) | 10,000 | 2.75 | 27.5K | 0 | — | ↗ |
| 2009-04-28 | WAUNG FRANK | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,500 | — | ↗ |
| 2008-02-01 | Zhang Yingwen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-02-01 | DONG BAOWEN | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-02-01 | BENNETT G MICHAEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-11-26 | Tsui Heung Mei | Director / 10% Owner | A-Award | D | Common Stock, par value $0.001 per share | 4,465,734 | 1.52 | 6.79M | 10,812,651 | — | ↗ |
| 2006-09-13 | Tsui Heung Mei | Director / 10% Owner | A-Award | D | Common Stock, par value $0.001 per share | 10,000,000 | 0.00 | — | 15,278,385 | — | ↗ |
| 2006-09-13 | Li Zhilin | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.001 per share | 10,000,000 | 0.00 | — | 10,000,000 | — | ↗ |
| 2006-05-16 | Tsui Heung Mei | Director / 10% Owner | A-Award | A | Common Stock | 4,723,056 | 0.00 | 4.7K | 25,278,385 | — | ↗ |
| 2005-10-19 | Yang Jian | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-10-19 | Wu Xinhua | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-10-19 | Tsui Heung Mei | Director | — | D | Common Stock | 0 | 0.00 | — | 20,555,329 | — | ↗ |
| 2005-10-19 | Li Zhilin | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-10-04 | Rosenberg Marat | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,828,170 | — | ↗ |
| 2005-10-04 | Halter Financial Investments LP | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,828,170 | — | ↗ |
| 2005-10-04 | Halter Financial Investments GP LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,828,170 | — | ↗ |
| 2005-10-04 | HALTER TIMOTHY P | Director / Officer | S-Sale | D | Common Stock, par value $0.001 per share | 1,828,170 | 0.10 | 182.8K | 0 | — | ↗ |
| 2005-10-04 | Diamond George L | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,828,170 | — | ↗ |
| 2005-10-04 | Brigante David F | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,828,170 | — | ↗ |
| 2005-05-11 | HALTER TIMOTHY P | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,875,045 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 300.0K | — | — | — | — | 16.0K | 316.0K | 0.00% | ↗ |
| 2 | 2023 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 3 | 2022 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 4 | 2021 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 5 | 2020 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 6 | 2019 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 7 | 2018 | Zhilin Li Chairman, Chief Executive Officer President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 8 | 2018 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 9 | 2017 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 10 | 2016 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 11 | 2016 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 12 | 2015 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
| 13 | 2014 | Zhilin Li Chairman, Chief Executive Officer, President and interim Chief Financial Officer | 225.6K | — | — | — | — | 16.0K | 241.6K | 0.00% | ↗ |
Proxy statements
| Filing date | Form type | Filing |
|---|---|---|
| 2025-11-14 | DEF 14A | ↗ |
| 2025-11-04 | PRE 14A | ↗ |
| 2024-11-12 | DEF 14A | ↗ |
| 2024-11-01 | PRE 14A | ↗ |
| 2023-11-07 | DEF 14A | ↗ |
| 2023-10-27 | PRE 14A | ↗ |
| 2022-11-14 | DEF 14A | ↗ |
| 2022-11-04 | PRE 14A | ↗ |
| 2021-11-15 | DEFA14A | ↗ |
| 2021-11-15 | DEF 14A | ↗ |
| 2020-11-16 | DEFA14A | ↗ |
| 2020-11-16 | DEF 14A | ↗ |
| 2019-11-06 | DEFA14A | ↗ |
| 2019-11-06 | DEF 14A | ↗ |
| 2018-10-25 | DEFA14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhilin Li | President, Chief Executive Officer, Chairman & Interim Chief Financial Officer | 316.0K | female |
| Huang Na | BOD Secretary & IR Manager | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CPHI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
